| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.07B | -10.2% |
| Gross profit | ¥0.01B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | -218.5% |
| Gross margin | 15.9% | Net margin -10.6% |
| Revenue Q/Q | -11.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.06B | 84.1% |
| R&D | ¥0.01B | 9.9% |
| SG&A | ¥0.01B | 22.0% |
| Tax & other | ¥0.00B | 0.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
利德曼 ・ ST荣科 ・ 百纳千成 ・ 吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份 ・ 海峡创新 ・ ST长方
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies